Pancreatic CT density is an optimal imaging biomarker for earlier detection of malignancy in the pancreas with intraductal papillary mucinous neoplasm
Copyright © 2022 IAP and EPC. Published by Elsevier B.V. All rights reserved..
BACKGROUND: Intraductal papillary mucinous neoplasms (IPMNs) are typically detected as incidental findings by computed tomography (CT); however, the conventional surveillance is not valid for the early detection of concomitant pancreatic cancer. The pancreas of IPMN is often accompanied by fatty infiltration in the parenchyma, and pancreatic fatty infiltration could be evaluated by pancreatic CT density (pancreatic index, PI). We aimed to investigate whether PI could be an imaging biomarker for the early prediction of malignancies in the pancreas with IPMN.
METHODS: Two different cohorts were investigated. (Investigation cohort): A total of 1137 patients with initially low-risk IPMN were compensated by initial IPMN findings, and 2 groups (malignancy/possible benign, 50 cases each) were investigated for yearly changes in PI and for the cutoff value of PI indicating the development of malignancies. (Validation cohort): To validate the cutoff value, 256 patients radiologically suspected of having IPMNs were investigated.
RESULTS: (Investigation-cohort): The malignancy group showed a gradual decrease in PI every year, and PI significantly differed among the 2 groups 1 year prior to the last investigation. The cutoff value of PI was set at 0.65. (Validation-cohort): A total of 55% of the patients with a PI below the cutoff value had malignancy in the pancreas, including concomitant pancreatic cancer, and the cutoff value was the most significant risk factors for the development of malignancies in the pancreas compared to the conventional risk factors for IPMN.
CONCLUSIONS: Decreasing PI would be an optimal imaging biomarker for earlier detection of malignancies in the pancreas with IPMN.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al. - 22(2022), 4 vom: 08. Mai, Seite 488-496 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yamada, Daisaku [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 11.05.2022 Date Revised 13.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.pan.2022.03.016 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339258195 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339258195 | ||
| 003 | DE-627 | ||
| 005 | 20231227130744.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.pan.2022.03.016 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM339258195 | ||
| 035 | |a (NLM)35396159 | ||
| 035 | |a (PII)S1424-3903(22)00105-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yamada, Daisaku |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pancreatic CT density is an optimal imaging biomarker for earlier detection of malignancy in the pancreas with intraductal papillary mucinous neoplasm |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.05.2022 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 IAP and EPC. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: Intraductal papillary mucinous neoplasms (IPMNs) are typically detected as incidental findings by computed tomography (CT); however, the conventional surveillance is not valid for the early detection of concomitant pancreatic cancer. The pancreas of IPMN is often accompanied by fatty infiltration in the parenchyma, and pancreatic fatty infiltration could be evaluated by pancreatic CT density (pancreatic index, PI). We aimed to investigate whether PI could be an imaging biomarker for the early prediction of malignancies in the pancreas with IPMN | ||
| 520 | |a METHODS: Two different cohorts were investigated. (Investigation cohort): A total of 1137 patients with initially low-risk IPMN were compensated by initial IPMN findings, and 2 groups (malignancy/possible benign, 50 cases each) were investigated for yearly changes in PI and for the cutoff value of PI indicating the development of malignancies. (Validation cohort): To validate the cutoff value, 256 patients radiologically suspected of having IPMNs were investigated | ||
| 520 | |a RESULTS: (Investigation-cohort): The malignancy group showed a gradual decrease in PI every year, and PI significantly differed among the 2 groups 1 year prior to the last investigation. The cutoff value of PI was set at 0.65. (Validation-cohort): A total of 55% of the patients with a PI below the cutoff value had malignancy in the pancreas, including concomitant pancreatic cancer, and the cutoff value was the most significant risk factors for the development of malignancies in the pancreas compared to the conventional risk factors for IPMN | ||
| 520 | |a CONCLUSIONS: Decreasing PI would be an optimal imaging biomarker for earlier detection of malignancies in the pancreas with IPMN | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Concomitant PDAC | |
| 650 | 4 | |a IPMN surveillance | |
| 650 | 4 | |a Pancreatic CT density | |
| 650 | 4 | |a Pancreatic fatty infiltration | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Pancreatic Hormones |2 NLM | |
| 700 | 1 | |a Kobayashi, Shogo |e verfasserin |4 aut | |
| 700 | 1 | |a Takahashi, Hidenori |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshioka, Teppei |e verfasserin |4 aut | |
| 700 | 1 | |a Iwagami, Yoshifumi |e verfasserin |4 aut | |
| 700 | 1 | |a Tomimaru, Yoshito |e verfasserin |4 aut | |
| 700 | 1 | |a Shigekawa, Minoru |e verfasserin |4 aut | |
| 700 | 1 | |a Akita, Hirofumi |e verfasserin |4 aut | |
| 700 | 1 | |a Noda, Takehiro |e verfasserin |4 aut | |
| 700 | 1 | |a Asaoka, Tadafumi |e verfasserin |4 aut | |
| 700 | 1 | |a Gotoh, Kunihito |e verfasserin |4 aut | |
| 700 | 1 | |a Tanemura, Masahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Doki, Yuichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Eguchi, Hidetoshi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al. |d 2001 |g 22(2022), 4 vom: 08. Mai, Seite 488-496 |w (DE-627)NLM119887509 |x 1424-3911 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:4 |g day:08 |g month:05 |g pages:488-496 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.pan.2022.03.016 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 4 |b 08 |c 05 |h 488-496 | ||